Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

Naval Daver, Jorge Cortes, Kate Newberry, Elias Jabbour, Lingsha Zhou, Xuemei Wang, Sherry Pierce, Tapan Kadia, Koji Sasaki, Gautam Borthakur, Farhad Ravandi, Naveen Pemmaraju, Hagop Kantarjian, and Srdan Verstovsek

Department of Leukemia and Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.126821
The online version of this article has a Supplementary Appendix. Manuscript received on March 16, 2015. Manuscript accepted on June 16, 2015. Correspondence: ndaver@mdanderson.org
SUPPLEMENTAL DATA

Patient Evaluation

The patient evaluation schedule included a complete physical examination (every 4 weeks for the first 3 cycles, then every 12 weeks), complete blood count and comprehensive biochemistry panel including liver function tests (every week for the first 2 cycles, then every 2 weeks for 4 cycles, then every 4 weeks thereafter), pregnancy test and counseling (pregnancy test every week for the first cycle and then every 4 weeks if regular menstrual cycles, or every 2 weeks if irregular menstrual cycles), bone marrow aspiration and biopsy with cytogenetics (prior to initiation of therapy and every 12 weeks, including staining for fibrosis) and molecular testing for JAK2<sup>V617F</sup> (every 12 weeks, if present before therapy). Bone marrow fibrosis and cellularity were graded according to the European consensus guidelines(29). The pyrosequencing assay to detect the 1849G>T JAK2 mutation (JAK2<sup>V617F</sup>) has been previously reported(32). Responses were assessed according to the 2006 IWG-MRT criteria(33).